01711nas a2200241   4500008004100000022001400041245007300055210006900128260000800197300001200205490000700217520095500224653003901179653001101218653000901229653001701238653001401255100002601269700002301295700002501318700002501343856010101368       2019                        eng d  a1061-186X00acRGD functionalized nanocarriers for targeted delivery of bioactives0 acRGD functionalized nanocarriers for targeted delivery of bioact  cFEB  a111-1240 v273 a<p>The integrins αvβ3 play a very imperative role in angiogenesis and are overexpressed in endothelial cells of the tumor. Recent years have witnessed huge exploration in the field of αvβ3 integrin-mediated bioactive targeting for treatment of cancer. In these studies, the cRGD peptide has been employed extensively owing to their binding capacity to the αvβ3 integrin. Principally, RGD-based approaches comprise of antagonist molecules of the RGD sequence, drug-RGD conjugates, and most importantly tethering of the nanocarrier surface with the RGD peptide as targeting ligand. Targeting tumor vasculature or cells via cRGD conjugated nanocarriers have emerged as a promising technique for delivering chemotherapeutic drugs and imaging agents for cancer theranostics. In this review, primary emphasis has been given on the application of cRGD-anchored nanocarriers for targeted delivery of drugs, imaging agents, etc. for tumor therapy.</p>
10aalpha(v)beta(3) integrin receptors10acancer10acRGD10ananocarriers10atargeting1 aGajbhiye, Kavita, Rai1 aGajbhiye, Virendra1 aSiddiqui, Imtiaz, A.1 aGajbhiye, Jayant, M.  uhttps://library.ncl.res.in/content/crgd-functionalized-nanocarriers-targeted-delivery-bioactives02536nas a2200229   4500008004100000022001400041245013200055210006900187260000800256300001100264490000800275520170400283653001801987653002802005653002902033653002702062100002102089700001802110700002302128700002702151856012802178       2023                        eng d  a0009-308400aChallenges and emerging strategies for next generation liposomal based drug delivery: an account of the breast cancer conundrum0 aChallenges and emerging strategies for next generation liposomal  cJAN  a1052580 v2503 a<p>
	The global cancer burden is witnessing an upsurge with breast cancer surpassing other cancers worldwide. Furthermore, an escalation in the breast cancer caseload is also expected in the coming years. The conventional therapeutic regimens practiced routinely are associated with many drawbacks to which nanotechnological in-terventions offer a great advantage. But how eminent could liposomes and their advantages be in superseding these existing therapeutic modalities? A solution is reflected in this review that draws attention to a decade-long journey embarked upon by researchers in this wake. This text is a comprehensive discussion of liposomes, the front runners of the drug delivery systems, and their active and passive targeting approaches for breast cancer management. Active targeting has been studied over the decade by many receptors overexpressed on the breast cancer cells and passive targeting with many drug combinations. The results converge on the fact that the actively targeted formulations exhibit a superior efficacy over their non-targeted counterparts and the all lipo-somal formulations are efficacious over the free drugs. This undoubtedly underlines the dominion of liposomal formulations over conventional chemotherapy. These investigations have led to the development of different liposomal formulations with active and passive targeting capacities that could be explored in depth. Acknowl-edging and getting a deeper insight into the liposomal evolution through time also unveiled many imperfections and unchartered territories that can be explored to deliver dexterous liposomal formulations against breast cancer and more in the clinical trial pipeline.</p>
10aBreast cancer10aLiposomal metamorphosis10aReceptor-ligand dynamics10aTargeted Drug Delivery1 aMoudgil, Aliesha1 aSalve, Rajesh1 aGajbhiye, Virendra1 aChaudhari, Bhushan, P.  uhttps://library.ncl.res.in/content/challenges-and-emerging-strategies-next-generation-liposomal-based-drug-delivery-account